Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +35

Bristol Myers Squibb stock: Revenue outlook rises as pipeline advances

Clinical trial results Earnings report Guidance lowered AI-generated analysis

πŸ“ˆ Bristol Myers Squibb reported third-quarter revenue of $13.07 billion, representing a 7% year-over-year increase that exceeded analyst forecasts.

πŸ’Š Eliquis sales surged 25% to $4.69 billion, serving as the primary driver for growth within the company's Growth Portfolio.

πŸ“‰ Management lowered adjusted EPS guidance for 2026 to $6.35–$6.55 due to acquisition-related charges and a contract termination fee.

πŸ’° The company raised its full-year 2026 revenue outlook to a range of $49.75 billion to $50.25 billion.

πŸ”¬ Bristol Myers Squibb plans to resume zolacabtagene autoleucel trials in early 2027 after resolving a manufacturing safety issue linked to a patient death.

🧠 Future growth catalysts include the potential expansion of Cobenfy into Alzheimer's disease and the development of milvexian.

Bullish Signals
  • Bristol Myers Squibb beat third-quarter revenue expectations with $13.07 billion in sales, driven by a 25% surge in Eliquis revenue to $4.69 billion.
  • The company raised its full-year 2026 revenue guidance to $49.75–$50.25 billion, signaling strong commercial momentum and demand for its growth portfolio.
Risk Factors
  • Adjusted EPS guidance was lowered to $6.35–$6.55 from the prior range of $6.75–$7.00 due to significant acquisition-related charges.
  • Adjusted gross margin declined to 68.4% from 72.9%, reflecting unfavorable product mix changes and a one-time charge associated with terminating a contract.
Full Analysis
Bristol Myers Squibb reported a strong third-quarter performance with revenue rising 7% year-over-year to $13.07 billion, surpassing analyst expectations of $12.75 billion. The company's Growth Portfolio drove significant momentum, with Eliquis revenue surging 25% to $4.69 billion, while the Legacy Portfolio grew 1% despite headwinds from older medicines. Despite the top-line beat, management lowered its adjusted earnings per share (EPS) guidance for 2026 to a range of $6.35 to $6.55, down from the previous forecast of $6.75 to $7.00. This reduction was primarily attributed to one-time acquisition-related charges and a specific charge linked to the termination of a contract, which also contributed to a decline in adjusted gross margin to 68.4%. Looking ahead, the company raised its full-year 2026 revenue outlook to between $49.75 billion and $50.25 billion, reflecting confidence in its pipeline and commercial execution. Key future catalysts include the potential expansion of Cobenfy into Alzheimer's disease treatment and the development of milvexian, with data expected next year. In the realm of oncology, Bristol Myers Squibb is working with the FDA to resume enrollment in trials for zolacabtagene autoleucel in early 2027. The company had previously paused these studies in September following a patient death but identified a manufacturing reagent as the root cause and adjusted the process accordingly.